​

Aprea Therapeutics (APRE) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

APRE Stock Rating

Aprea Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 2 Hold (25.00%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 2 4 Strong Sell Sell Hold Buy Strong Buy

APRE Price Target Upside V Benchmarks

TypeNameUpside
StockAprea Therapeutics-
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.50$1.50$1.50
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2521---3
Mar, 2521---3
Feb, 2521---3
Jan, 2521---3
Dec, 2421---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 10, 2023Loop Capital MarketsBuyinitialise
Jul 08, 2022WedbushOutperforminitialise
Dec 29, 2020Morgan StanleyEqual-WeightEqual-Weighthold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.95$-2.35----
Avg Forecast$-3.42$-2.51$-1.46$-1.48$-1.13$-0.82
High Forecast$-2.07$-2.35$-1.46$-0.73$-0.61$-0.82
Low Forecast$-4.76$-2.66$-1.46$-2.23$-1.64$-0.82
Surprise %15.50%-6.37%----

Revenue Forecast

$0 $3M $6M $9M $12M $15M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$583.23K-----
Avg Forecast$689.67K$1.34M$900.00K$900.00K$1.80M$10.84M
High Forecast$850.27K$1.55M$900.00K$900.00K$1.80M$10.84M
Low Forecast$529.06K$1.12M$900.00K$900.00K$1.80M$10.84M
Surprise %-15.43%-----

Net Income Forecast

$-20M $-16M $-12M $-8M $-4M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-14.29M$-12.96M----
Avg Forecast$-14.29M$-9.06M$-5.29M$-5.35M$-4.07M$-2.97M
High Forecast$-7.50M$-8.51M$-5.29M$-2.65M$-2.21M$-2.97M
Low Forecast$-17.23M$-9.61M$-5.29M$-8.05M$-5.93M$-2.97M
Surprise %-42.99%----

APRE Forecast FAQ

Is Aprea Therapeutics stock a buy?

Aprea Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Aprea Therapeutics is a favorable investment for most analysts.

What is Aprea Therapeutics's price target?

Aprea Therapeutics's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $1.5.

How does Aprea Therapeutics stock forecast compare to its benchmarks?

Aprea Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Aprea Therapeutics over the past three months?

  • April 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Aprea Therapeutics’s EPS forecast?

Aprea Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.46, marking a -37.87% decrease from the reported $-2.35 in 2024. Estimates for the following years are $-1.48 in 2026, $-1.13 in 2027, and $-0.82 in 2028.

What is Aprea Therapeutics’s revenue forecast?

Aprea Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $900K, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $900K, followed by $1.8M for 2027, and $10.84M for 2028.

What is Aprea Therapeutics’s net income forecast?

Aprea Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-5.294M, representing a -59.15% decrease from the reported $-12.959M in 2024. Projections indicate $-5.354M in 2026, $-4.07M in 2027, and $-2.966M in 2028.